Eledon Pharmaceuticals Inc ELDN Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$2.61 up $0.15, 5.89% at close Nov 6
Last close · Previous close $2.46
- Market cap
- At the Nov 6 close
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$2.61up $0.15, 5.89%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.46Nov 5
- Volume690.43KNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume919.98KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.35 to $4.49; now $2.61
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ELDN beat the S&P 500 in 3 of 7 periods.
| Period | ELDN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ELDN: up 6.3% S&P 500: down 5.6% | ELDN beat the S&P 500 by 11.9 percentage points Beat |
| 3M | ELDN: down 24.7% S&P 500: down 4.1% | ELDN trailed the S&P 500 by 20.6 percentage points Trailed |
| YTD | ELDN: up 72.5% S&P 500: up 8.7% | ELDN beat the S&P 500 by 63.8 percentage points Beat |
| 1Y | ELDN: down 36.5% S&P 500: up 10.9% | ELDN trailed the S&P 500 by 47.4 percentage points Trailed |
| Long term | ||
| 3Y | ELDN: up 113.5% S&P 500: up 75.0% +28.8% vs +20.5% a year | ELDN beat the S&P 500 by 38.5 percentage points Beat |
| 5Y | ELDN: down 47.6% S&P 500: up 67.8% −12.1% vs +10.9% a year | ELDN trailed the S&P 500 by 115.4 percentage points Trailed |
| 10Y | ELDN: down 98.3% S&P 500: up 313.1% −33.3% vs +15.2% a year | ELDN trailed the S&P 500 by 411.4 percentage points Trailed |
$10,000 invested in ELDN 10 years ago (Nov 4, 2016) would be worth about $174 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
ELDN beat the S&P 500 in 3 of 7 periods.
| Period | ELDN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ELDN: up 6.3% S&P 500: down 5.6% | ELDN beat the S&P 500 by 11.9 percentage points Beat |
| 3M | ELDN: down 24.7% S&P 500: down 4.3% | ELDN trailed the S&P 500 by 20.4 percentage points Trailed |
| YTD | ELDN: up 72.5% S&P 500: up 7.8% | ELDN beat the S&P 500 by 64.7 percentage points Beat |
| 1Y | ELDN: down 36.5% S&P 500: up 9.7% | ELDN trailed the S&P 500 by 46.2 percentage points Trailed |
| Long term | ||
| 3Y | ELDN: up 113.5% S&P 500: up 68.8% +28.8% vs +19.1% a year | ELDN beat the S&P 500 by 44.7 percentage points Beat |
| 5Y | ELDN: down 47.6% S&P 500: up 56.9% −12.1% vs +9.4% a year | ELDN trailed the S&P 500 by 104.5 percentage points Trailed |
| 10Y | ELDN: down 98.3% S&P 500: up 252.6% −33.3% vs +13.4% a year | ELDN trailed the S&P 500 by 350.9 percentage points Trailed |
$10,000 invested in ELDN 10 years ago (Nov 4, 2016) would be worth about $174 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$3,849.12
Closing high on . Now 99.9% below that record.
Split-adjusted daily closes since Sep 17, 2014.
Stock splits
2
Latest: 1-for-18 on . Share counts adjust after each split.
Both splits
- 1-for-18
- 1-for-9
Valuation
Financials
About Eledon Pharmaceuticals Inc
Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company’s lead compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4 + T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4 + lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which is especially important for autoimmune diseases and in the transplant setting. Furthermore AT-1501 is an IgG1 antibody specifically engineered to cripple the Fc effector function to potentially improve safety, as well as potentially provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other approaches.
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ELDN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
- More stocks
- APMC Ampercap Acquisition Company
- APMCU Ampercap Acquisition Co - Units (1 Ord Cls & 1 Rts)
- APMI AxonPrime Infrastructure Acquisition Corp - Class A
- APMIU AxonPrime Infrastructure Acquisition Corp - Units (1 Ord Share Class A & 1/3 War)
- APNC Apeiron Capital Investment Corp - Class A
- APNCU Apeiron Capital Investment Corp - Units (1 Ord Share Class A & 1/2 War)
ELDN stock FAQ
What is ELDN stock’s price today?
Eledon Pharmaceuticals (ELDN) traded at $2.61 at the close on , up $0.15 (5.89%) from the previous close of $2.46. Over the past 52 weeks it has traded between $1.35 and $4.49.
If you invested $1,000 in ELDN 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ELDN on would be worth about $17 at the close on , a total return of −98.3%. The same $1,000 would be worth $524 if invested five years ago and $635 if invested one year ago. Past performance doesn’t predict future returns.
Does ELDN pay a dividend?
Eledon Pharmaceuticals hasn’t paid a dividend in the last twelve months.
What is ELDN’s 52-week high and low?
Over the past 52 weeks ELDN has traded as low as $1.35 and as high as $4.49. At $2.61 at the close on , it is 42.0% below that high and 93.0% above the low.
What is ELDN’s all-time high?
ELDN’s highest closing price was $3,849.12 on , adjusted for stock splits. At $2.61 at the close on , it is 99.9% below that record.
Has ELDN stock ever split?
Yes, twice: 1-for-9 on ; 1-for-18 on .
How has ELDN stock performed?
Including dividends and measured to the close on , ELDN has returned +72.5% so far this year and −36.5% over the past year, and −47.6% over five years (−12.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What exchange does ELDN trade on?
Eledon Pharmaceuticals trades on the Nasdaq under the ticker symbol ELDN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.